Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
Juan W. Valle(Cancer Research UK Manchester Institute), John Bridgewater(University College London Hospitals NHS Foundation Trust), Justin S. Waters(Maidstone Hospital), Daniel H. Palmer(University of Liverpool), Alison Backen(Cancer Research UK), Andre Lopes(Cancer Research UK), Caroline Dive(University of Manchester), David Cunningham(Royal Marsden NHS Foundation Trust), Pippa Corrie(University of Cambridge), Anthony Maraveyas(University of Hull), Harpreet Wasan(Hammersmith Hospital), Marian Duggan(Cancer Research UK), Alan Anthoney(St James's University Hospital), Paul J. Ross(King's College Hospital NHS Foundation Trust), Karen Morris(Cancer Research UK Manchester Institute), W P Steward(University of Leicester), Sandy Beare(King's College London), Charlotte Rees(University of Southampton), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
Cited by 282
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k